Success! The link has been copied to your clipboard.
Fresenius Medical Care North America Announces New President for Renal Therapies Group
News Release | Published: 7.22.2021
Patient Care
We deliver high-quality care with innovation and empathy.
We deliver high-quality care with innovation and empathy.
PRACTICE SUPPORT
Products
Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Insights
Our Company
More
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Success! The link has been copied to your clipboard.
News Release | Published: 7.22.2021
WALTHAM, Mass. – July 22, 2021 – Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products, announced today that Joseph (Joe) Turk has been named President for the company’s Renal Therapies Group.
In his new role, Turk will be responsible for overseeing Renal Products and Pharmaceutical operations, including sales, clinical support, product marketing and management, customer and technical services, and regulatory affairs.
Having previously served as FMCNA’s President of Home and Critical Care Therapies, these expanded responsibilities align the company’s products teams into one organization – with a focus on efficiently and effectively delivering new technologies to support people living with kidney disease.
“Joe’s decades of strategy and market development experience have been critical in expanding our footprint and technologies in home dialysis and critical care since he joined us as part of the NxStage merger in 2019,” said Bill Valle, Chief Executive Officer, FMCNA. “Joe’s leadership will be instrumental as we focus on better leveraging best practices across divisions for the benefit of our customers, partners, field teams, and most importantly our patients.”
Turk succeeds Mark Costanzo, who recently retired as President of FMCNA’s Renal Therapies Group.
“I am thrilled to bring our exceptional teams together at this important time,” said Turk. “We have an incredible opportunity as the market leader to work together to ensure we’re providing the highest quality care and renal products to the patients we are privileged to serve.”
To learn more about FMCNA and its leadership, please visit fmcna.com/company/.
About Fresenius Medical Care North America
Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com/.
© 2006-2023 Fresenius Medical Care. All Rights Reserved.